- Home
- RNXT
RNXT
RenovoRx Inc.
as 12-18-2024 1:41pm EST
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 30.0M | IPO Year: | 2021 |
| Target Price: | $6.50 | AVG Volume (30 days): | 118.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.68 - $2.35 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RenovoRx Inc. News
RNXT Breaking Stock News: Dive into RNXT Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
GlobeNewswire
9 days ago
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET
Medical Device Network
13 days ago
RenovoRx begins commercialisation of RenovoCath device
GlobeNewswire
14 days ago
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System
MT Newswires
a month ago
RenovoRx Says Northwell Health Cancer Institute Begins Enrolling Patients for Phase III Pancreatic Cancer Trial
GlobeNewswire
a month ago
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
GlobeNewswire
a month ago
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
Simply Wall St.
3 months ago
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully
Compare RNXT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.